Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.48. Following the transaction, the chief operating officer now directly owns 323,310 shares in the company, valued at $6,931,766.40. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Anish Patel also recently made the following trade(s):
- On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31.
- On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total transaction of $524,706.00.
Enliven Therapeutics Stock Up 2.1 %
Shares of Enliven Therapeutics stock opened at $20.69 on Wednesday. Enliven Therapeutics, Inc. has a 12-month low of $10.90 and a 12-month high of $30.03. The stock has a market cap of $1.01 billion, a P/E ratio of -10.89 and a beta of 1.04. The business's 50 day moving average is $21.76 and its 200-day moving average is $23.86.
Institutional Investors Weigh In On Enliven Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ELVN. Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics during the 4th quarter worth approximately $15,106,000. FMR LLC boosted its stake in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after acquiring an additional 601,611 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth approximately $8,199,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after acquiring an additional 313,019 shares during the period. Institutional investors own 95.08% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on ELVN. Robert W. Baird raised their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, November 15th. BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a "buy" rating and a $42.00 price target for the company. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $38.25.
View Our Latest Report on ELVN
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
